COMP <GO>
HCM vs RCUS // PIOTROSKI F-SCORE QUALITY
HUTCHMED (China) Limited (NASDAQ) VS. Arcus Biosciences Inc. (NYSE) • 15-METRIC TALLY: HCM 8
— RCUS 0
▲ PIOTROSKI F-SCORE QUALITY LEADER: HCM
LAST: $13.59 (+2.03%) • MKT CAP: $2.37B
piotroski-score
4/9
LAST: $18.61 (+1.20%) • MKT CAP: $2.37B
piotroski-score
1/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HCM VS. RCUS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HCM | RCUS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -2.50% | -35.00% | +32.50 | HCM | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.32% | -20.42% | +17.10 | HCM | /fcf-yield <GO> |
| Operating Margin | -7.10% | -60.00% | +52.90 | HCM | /operating-margins <GO> |
| Net Profit Margin | 68.00% | -60.00% | +128.00 | HCM | /net-margins <GO> |
| Revenue Growth (YoY) | -13.00% | -35.30% | +22.30 | HCM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.63 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 4/9 | 1/9 | +3.00 | HCM | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.1 | 30.0 | +11.04 | HCM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 4.8x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.37B | $2.37B | $1.3M | HCM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HCM REV | RCUS REV | HCM GROSS % | RCUS GROSS % | HCM FCF | RCUS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $548.5M | $33.0M | 38.7% | — | -$78.8M | -$484.0M |
| FY 2024 | $630.2M | $51.0M | 44.6% | — | -$17.4M | -$176.0M |
| FY 2023 | $838.0M | $37.0M | — | — | $219.3M | -$306.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HCM // BETA —
RCUS // BETA —